5 completed, 1 no longer available, 1 terminated. 4 Phase 3, 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 3, Terminated 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow ISIS 304801: new trials by email Literature Review of ISIS 304801 trials Research Report on ISIS 304801
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers Volanesorsen, Moxifloxacin, Placebo - Abnormalities, Cardiovascular | Phase 1 | Completed | Ionis Pharmaceuticals, Inc. | 52 | 2016-09-19 | 2022-01-28 |
| The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy volanesorsen, Placebo - Familial Partial Lipodystrophy | Phase 2 / Phase 3 | Terminated | Akcea Therapeutics | 40 | 2015-12-28 | 2021-10-18 |
| Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension ISIS 304801, Placebo - Lipodystrophy | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 5 | 2015-12-23 | 2020-10-20 |
| The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome Volanesorsen - Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency | Phase 3 | Completed | Akcea Therapeutics | 68 | 2015-12-23 | 2021-08-26 |
| The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia Volanesorsen, Placebo - Hypertriglyceridemia | Phase 3 | Completed | Ionis Pharmaceuticals, Inc. | 114 | 2015-02-05 | 2022-04-13 |
| The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome Volanesorsen, Placebo - Familial Chylomicronemia Syndrome | Phase 3 | Completed | Ionis Pharmaceuticals, Inc. | 67 | 2014-12-01 | 2022-04-13 |
| Volanesorsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS) Volanesorsen - Familial Chylomicronemia | No longer available | Akcea Therapeutics | 2021-09-16 |
Familial hyperchylomicronemia syndrome (3) · Hyperlipoproteinemia Type I (2) · Hypertriglyceridemia (2) · Cardiovascular Abnormalities (1) · Dyslipidemias (1) · Genetic Diseases, Inborn (1) · Hyperlipidemias (1) · Hyperlipoproteinemias (1) · Lipid Metabolism Disorders (1) · Lipid Metabolism, Inborn Errors (1) · Lipodystrophy (1) · Lipodystrophy, Familial Partial (1) · Metabolic Diseases (1) · Metabolism, Inborn Errors (1)
Akcea Therapeutics (3) · Ionis Pharmaceuticals, Inc. (3) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)
United States (6) · Canada (4) · Germany (4) · Netherlands (4) · Brazil (3) · France (3) · United Kingdom (3) · Israel (2) · Italy (2) · South Africa (2) · Spain (2) · Belgium (1) · Hungary (1) · Russia (1)
PMID 37164837, PMID 27271183, PMID 29748148, PMID 31390500, PMID 33798466, PMID 36195542
2014 (2), 2015 (2)